-$0.61 EPS Expected for Titan Medical Inc. (NASDAQ:TMDI) This Quarter

Share on StockTwits

Equities research analysts predict that Titan Medical Inc. (NASDAQ:TMDI) will report ($0.61) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Titan Medical’s earnings, with the lowest EPS estimate coming in at ($0.72) and the highest estimate coming in at ($0.49). Titan Medical posted earnings per share of ($0.41) during the same quarter last year, which indicates a negative year over year growth rate of 48.8%. The business is expected to issue its next earnings results on Monday, November 11th.

On average, analysts expect that Titan Medical will report full year earnings of ($2.32) per share for the current financial year, with EPS estimates ranging from ($2.89) to ($1.75). For the next financial year, analysts anticipate that the company will post earnings of ($1.25) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Titan Medical.

Titan Medical (NASDAQ:TMDI) last posted its earnings results on Wednesday, July 31st. The company reported $0.25 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.89.

Several research firms recently commented on TMDI. ValuEngine upgraded Titan Medical from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Northland Securities restated a “buy” rating on shares of Titan Medical in a research report on Thursday, July 18th. Piper Jaffray Companies began coverage on Titan Medical in a research report on Wednesday, May 22nd. They set an “overweight” rating and a $6.00 target price for the company. Finally, Zacks Investment Research downgraded Titan Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Titan Medical currently has a consensus rating of “Buy” and an average price target of $5.56.

A hedge fund recently raised its stake in Titan Medical stock. Morgan Stanley raised its holdings in Titan Medical Inc. (NASDAQ:TMDI) by 27.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,342 shares of the company’s stock after purchasing an additional 7,301 shares during the quarter. Morgan Stanley owned approximately 0.16% of Titan Medical worth $81,000 as of its most recent SEC filing. 8.73% of the stock is currently owned by institutional investors and hedge funds.

Shares of Titan Medical stock traded up $0.04 during midday trading on Monday, hitting $2.10. 200 shares of the company were exchanged, compared to its average volume of 201,904. The firm has a market cap of $44.43 million, a P/E ratio of -1.54 and a beta of 5.00. Titan Medical has a 52 week low of $1.05 and a 52 week high of $4.65. The firm has a 50 day simple moving average of $2.13 and a 200-day simple moving average of $2.53.

Titan Medical Company Profile

Titan Medical Inc, a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures.

Featured Article: Does the Dogs of the Dow strategy work?

Get a free copy of the Zacks research report on Titan Medical (TMDI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Titan Medical (NASDAQ:TMDI)

Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pirl Price Hits $0.0096
Pirl Price Hits $0.0096
Weekly Research Analysts’ Ratings Updates for STMicroelectronics
Weekly Research Analysts’ Ratings Updates for STMicroelectronics
Zacks: Brokerages Anticipate RPC, Inc.  Will Post Quarterly Sales of $345.56 Million
Zacks: Brokerages Anticipate RPC, Inc. Will Post Quarterly Sales of $345.56 Million
GSI Technology  Raised to “Sell” at ValuEngine
GSI Technology Raised to “Sell” at ValuEngine
Dover  Lowered to Sell at ValuEngine
Dover Lowered to Sell at ValuEngine
Aclaris Therapeutics  Receives “Buy” Rating from William Blair
Aclaris Therapeutics Receives “Buy” Rating from William Blair


 
© 2006-2019 Zolmax.